<DOC>
	<DOCNO>NCT02657122</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics single ascend dos multiple ascend dos investigational drug TD-1473 compare placebo healthy subject .</brief_summary>
	<brief_title>SAD MAD Study Evaluate Safety , Tolerability , Pharmacokinetics ( PK ) TD-1473 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female 19 55 year old Willing able give inform consent Body Mass Index ( BMI ) 18 30 kg/m2 Women child bear potential must negative pregnancy test either abstain sex use highly effective method birth control Additional inclusion criterion apply Positive hepatitis A , B , C , HIV , tuberculosis ( TB ) Clinically significant abnormality baseline result laboratory evaluation Evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease Participated another clinical trial investigational drug ( medical device ) within 30 day prior Screening ( within 60 day prior Screening investigational drug biologic ) , currently participate another trial investigational drug ( medical device ) Use prescription drug chronic counter medication within 14 day prior clinic admission require continue use study participation , exception hormonal contraceptive hormone replacement therapy . Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Single ascend dose</keyword>
	<keyword>SAD</keyword>
	<keyword>multiple ascend dose</keyword>
	<keyword>MAD</keyword>
	<keyword>Phase 1</keyword>
	<keyword>first-in-human</keyword>
	<keyword>volunteer</keyword>
	<keyword>TD-1473</keyword>
</DOC>